ClinicalTrials.gg
CompletedNCT07421258TATOOUpdated Oct 5, 2026

A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting

An observational study in Crohn's Disease and Ulcerative Colitis, sponsored by AbbVie. Completed at 5 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by AbbVie · Observational

How we know

Updated Oct 5, 2026Now CompletedFirst site in Japan+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
1,638
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Enrollment
5th of 26
1,638 · median 252
Started
2026
with 1 other
Observational
26 of 55
3 open now
Registered
54th of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 5th largest by enrollment of the 26 observational ones that give a count, is one of 2 that started in 2026, is one of 26 observational ones, and was the 54th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

Inflammatory Bowel Disease (IBD), encompassing Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic, relapsing, and often disabling condition characterized by inflammation of the gastrointestinal tract. A treat-to-target strategy (T2T) is recommended by international guidelines to optimize long-term outcomes in IBD. The purpose of this study is to describe the real-life implementation of T2T in IBD worldwide and the association between using a T2T strategy and disease outcomes.

This is a multi-country, observational, retrospective (non-interventional) study with a cross-sectional component based upon a sample of adult participants with IBD. All objectives will be assessed for IBD and then for CD/UC separately. Primary and secondary objectives will be assessed for the overall population over the 24 months study period.

As this is an observational study, enrolled participants will be managed and followed up according to the standard practice.

Retrospective chart review over the 24-months from date of inclusion will allow us to collect the variables of interest by using an e-CRF. There will be no additional burden for participants in this trial. Study visits will not be required as this is a retrospective chart review.

03

Conditions studied

  • Crohn's Disease
  • Ulcerative Colitis

Keywords

  • Inflammatory Bowel Disease
  • Crohn's Disease
  • Ulcerative Colitis
  • Treat-to-Target
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants with a physician-confirmed diagnosis of Ulcerative Colitis (UC) or Crohn's Disease (CD) >= 2 years prior to enrolment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male and female participants (>= 18 years old) at the inclusion date who present within the usual course of care
  • Participants able to provide voluntary prior to any study data collection
  • Participant diagnosed with Crohn's Disease (CD) or Ulcerative Colitis (UC) for at least 24 months at the inclusion date
  • With >= 24 months of available medical records from the inclusion date

Exclusion criteria

Exclusion Criteria:

  • Participants who had received treatment with any drug/device/intervention over the past 24 months prior to the enrolment
  • Participants under legal protection
  • History of proctocolectomy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
1,638 participants (actual)

Groups and cohorts

  • Adults with Inflammatory Bowel Disease

    Participants will be managed and followed according to the standard practice.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Managed Using Treat-to-Target (T2T)

    Defined as a participant with a therapeutic modification \[dose escalation, change in therapy\] within 12 weeks following any objective disease monitoring that demonstrated active disease.

    Time frame: 12 Weeks

07

Study locations

5 sites
  • Chongqing General Hospital /ID# 282777
    Chongqing, Chongqing Municipality 400013, China
  • Centre Hospitalier Universitaire de Nimes - Hopital Universitaire Caremeau /ID# 282775
    Nîmes, Gard 300000, France
  • Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 280265
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
  • CHU Amiens-Picardie Site Sud /ID# 280263
    Amiens, Somme 80054, France
  • Kitasato University Kitasato Institute Hospital /ID# 282803
    Minato-ku, Tokyo 108-8642, Japan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Sep 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Feb 19, 2026
StartActual
Feb 9, 2026
Primary completionActual
Sep 1, 2026
CompletionActual
Sep 1, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Sites
3 sites added, 2 sites removed — first site in Japan
Show 3 added (2 France, 1 Japan)
  • Centre Hospitalier Universitaire de Nimes - Hopital Universitaire Caremeau /ID# 282775 · Nîmes, France
  • Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 280265 · Vandœuvre-lès-Nancy, France
  • Kitasato University Kitasato Institute Hospital /ID# 282803 · Minato-ku, Japan
Show 2 removed
  • Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau /ID# 282775 · Nîmes, France
  • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 280265 · Vandœuvre-lès-Nancy, France
Oct 5, 2026
Enrollment
2000 (estimated)→1638 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    3 sites added, 2 sites removed — first site in Japan
    Show 3 added (2 France, 1 Japan)
    • Centre Hospitalier Universitaire de Nimes - Hopital Universitaire Caremeau /ID# 282775 · Nîmes, France
    • Centre Hospitalier Regional Universitaire de Nancy - Hopitaux de Brabois /ID# 280265 · Vandœuvre-lès-Nancy, France
    • Kitasato University Kitasato Institute Hospital /ID# 282803 · Minato-ku, Japan
    Show 2 removed
    • Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau /ID# 282775 · Nîmes, France
    • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois /ID# 280265 · Vandœuvre-lès-Nancy, France
    Enrollment 2000 (estimated)→1638 (actual)
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07421258
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Feb 9, 2026
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026
Last update
Oct 5, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion